The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel

2008 ◽  
Vol 66 (3) ◽  
pp. 504-515 ◽  
Author(s):  
Q.-Q. Li ◽  
X.-X. Cao ◽  
J.-D. Xu ◽  
Q. Chen ◽  
W.-J. Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Prion Protein ◽  
Protein Interaction ◽  
Breast Cancer Cells ◽  
Multidrug Resistant ◽  
Cellular Prion Protein ◽  
P Glycoprotein

scholarly journals Suppression of αvβ6 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs

Neoplasma ◽  
2020 ◽  
Vol 67 (02) ◽  
pp. 379-388 ◽  
Author(s):  
Y.H. ZHANG ◽  
Z.F. GAO ◽  
G.H. DONG ◽  
X. LI ◽  
Y. WU ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Anticancer Drugs ◽  
Breast Cancer Cells ◽  
Multidrug Resistant ◽  
P Glycoprotein

scholarly journals Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Daoxia Guo ◽  
Xiaoyuan Ji ◽  
Fei Peng ◽  
Yiling Zhong ◽  
Binbin Chu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Rna Interference ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Silicon Nanoparticles ◽  
Multidrug Resistant ◽  
Rnase A ◽  
Drug Resistant ◽  
Fluorescent Silicon Nanoparticles ◽  
P Glycoprotein

Abstract The development of effective and safe vehicles to deliver small interfering RNA (siRNA) and chemotherapeutics remains a major challenge in RNA interference-based combination therapy with chemotherapeutics, which has emerged as a powerful platform to treat drug-resistant cancer cells. Herein, we describe the development of novel all-in-one fluorescent silicon nanoparticles (SiNPs)-based nanomedicine platform for imaging-guided co-delivery of siRNA and doxorubicin (DOX). This approach enhanced therapeutic efficacy in multidrug-resistant breast cancer cells (i.e., MCF-7/ADR cells). Typically, the SiNP-based nanocarriers enhanced the stability of siRNA in a biological environment (i.e., medium or RNase A) and imparted the responsive release behavior of siRNA, resulting in approximately 80% down-regulation of P-glycoprotein expression. Co-delivery of P-glycoprotein siRNA and DOX led to > 35-fold decrease in the half maximal inhibitory concentration of DOX in comparison with free DOX, indicating the pronounced therapeutic efficiency of the resultant nanocomposites for drug-resistant breast cancer cells. The intracellular time-dependent release behaviors of siRNA and DOX were revealed through tracking the strong and stable fluorescence of SiNPs. These data provide valuable information for designing effective RNA interference-based co-delivery carriers.

scholarly journals The Role of CD44 and ERM Proteins in Expression and Functionality of P-glycoprotein in Breast Cancer Cells

Molecules ◽  
2016 ◽  
Vol 21 (3) ◽  
pp. 290 ◽  
Author(s):  
Deep Pokharel ◽  
Matthew Padula ◽  
Jamie Lu ◽  
Ritu Jaiswal ◽  
Steven Djordjevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Erm Proteins ◽  
P Glycoprotein

P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells

2014 ◽  
Vol 87 (2) ◽  
pp. 292-302 ◽  
Author(s):  
Fei Zhang ◽  
Haichang Zhang ◽  
Zhiyong Wang ◽  
Man Yu ◽  
Ran Tian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Multidrug Resistant ◽  
P Glycoprotein

Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs

2005 ◽  
Vol 65 (9) ◽  
pp. 3861-3867 ◽  
Author(s):  
Valérie Gouazé ◽  
Yong-Yu Liu ◽  
Carlton S. Prickett ◽  
Jing Y. Yu ◽  
Armando E. Giuliano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Anticancer Drugs ◽  
Breast Cancer Cells ◽  
Multidrug Resistant ◽  
Glucosylceramide Synthase ◽  
P Glycoprotein
Sign in / Sign up

Export Citation Format

Share Document